Cristiana Vitale, Gabriele Fragasso, Izabella Uchmanowicz, Angela Sciacqua, Pablo Díez‐Villanueva, Shirley Sze, Quin E. Denfeld, Markus S. Anker, Elena Marques-Sule, Anna Strömberg, Emanuelle Berthelot, Stephan von Haehling, Giuseppe Rosano, Wolfram Doehner, Yuhui Zhang, Camilla Hage
This paper discusses the considerations for multidimensional and multidisciplinary management of heart failure (HF) patients with frailty. Frailty is a multidimensional, dynamic and potentially reversible state, defined by clinical, functional, psycho-cognitive and social domains. Frailty is seldom systematically assessed in clinical practice in HF patients. Paradoxically, although the absolute benefit of HF guideline-directed medical treatment in frail HF patients seems greater, it is under-prescribed. This therapeutic gap could be related to different reasons, such as concerns about safety, polypharmacy and the lack of specific evidence-based data. Frail HF patients require a comprehensive, multidimensional therapeutic strategy that integrates available evidence-based pharmacological interventions with targeted non-pharmacological modalities across multiple clinical disciplines to optimise patient outcomes. The four domains of frailty should be objectively and routinely assessed with a multidimensional approach to facilitate a more individualised and comprehensive care plan delivered by a multidisciplinary team. In the future, we need more dedicated studies and randomised clinical trials that include frail HF patients.